Blue Cross of Idaho was among the investors in a series B round that took the healthcare analytics platform operator's overall funding to more than $26m

Roche Venture Fund has taken part in a $38.7m round that will fund sales and commercialisation of MacuLogix's AMD diagnostics system.

Oxford-founded biopharmaceutical development instrument manufacturer Refeyn has secured funding from the university and OSI to help scale manufacturing and distribution.

Zurich brain injury antibody spinout NovaGo has extended its strategic partnership with immunotherapy company Neurimmune by securing its support in a series A round.

Building on early development funding from TAU’s Technology Innovation Momentum Fund, Trobix Bio has spun out to commercialise an approach to overcoming antibacterial resistance.

Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.

Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.

The genomic medicine developer plans to raise up to $100m in an upcoming IPO that could hand exits to Amgen Ventures, Brace Pharma Capital and Baxter Ventures.

Singtel Group and WuXi Apptec both contributed to a UOB-led round that increased the online healthcare platform's overall funding to $78m.

University of Utah’s TVC commercialisation office is to open a new incubator with Recursion, itself a Utah spinout, to provide facilities including wet lab and co-working space.